Get Help Sign In
ProcessingProcessing

IDT Leadership

Photograph of Trey Martin

Trey Martin

President – Integrated DNA Technologies (IDT)

No one understands the value of IDT – and IDT employees – better than Trey. After all, he started as an intern more than 25 years ago, and has since accumulated hands-on experience in almost every department. Trey was appointed President in April 2018, following the acquisition of IDT by Danaher.

Trey joined IDT in 1994, while earning his bachelor’s degree in Biochemistry at the University of Iowa. He initially served as a Production Scientist, but his career wove through the hallways, labs and offices of IDT, allowing him to acquire extensive experience in most functional units of the company, including engineering, process automation, chemistry, genomics applications, facilities design, construction, commercial real estate, M&A, IR and executive finance.

Trey was appointed Chief Operating Officer in 2006. His responsibilities as COO included oversight of global operations, process development, strategic planning, BoD reporting, customer service, sales, strategic partnerships, and corporate representation for our Founder.

Photograph of Mark Behlke

Mark Behlke

MD, PhD, Chief Scientific Officer (CSO)

IDT’s Chief Scientific Officer is an internationally-recognized expert in the field of nucleic acid technologies and an inventor cited on more than 50 US Patents. In nearly 25 years at IDT, Mark has overseen research programs and new product development in the areas of DNA thermodynamics, gene synthesis, probe chemistry, qPCR, NGS, antisense, RNA interference, and CRISPR genome editing.

Mark joined IDT as an R&D consultant in 1995 and was named VP R&D in 1996. He was promoted to CSO in 2013.

Mark is an author on more than 130 peer-reviewed scientific manuscripts and seven book chapters, and he is a scientific co-founder of Dicerna Pharmaceuticals, an RNAi Therapeutics company. Mark earned his Bachelor of Science degree in Biology from Massachusetts Institute of Technology in 1981. He was awarded MD & PhD degrees in 1987 from the Washington University School of Medicine in St. Louis after doing his doctoral dissertation in the field of Immunogenetics in the laboratory of Prof. Dennis Loh. Mark completed post-graduate studies in Boston as an intern and resident physician in Internal Medicine at Brigham and Women’s Hospital, and as an Endocrinology Fellow in the Harvard Longwood program. He was a Howard Hughes Postdoctoral Fellow in Human Genetics in the Laboratory of David Page at the Whitehead Institute for Biomedical Research(1991-1995).

Photograph of Roman Terrill

Roman Terrill

Senior Vice President, Products and Services

Roman has been part of IDT for more than two decades and was appointed Senior Vice President of Products and Services in April 2018, following the acquisition of IDT by Danaher.

He joined IDT in 1998 as Legal Counsel and held several progressive legal and business unit positions prior to serving as General Counsel from 2002 until 2016. In 2006, Roman was named Business Unit Leader for the GMP division, which addresses the clinical diagnostic market.

Roman earned his bachelor’s degree in Russian Literature and his Juris Doctorate at the University of Iowa.

Photograph of Raj Kapadia

Raj Kapadia

Vice President, Global Sales and Marketing

Raj joined Integrated DNA Technologies IDT as Vice President of Global Sales and Marketing in March 2020.

Raj comes to IDT from Beckman Coulter Life Sciences where he played a critical role in completing three key acquisitions, clarifying Beckman Coulter Life Science's strategic plan to accelerate to double digit growth, and building innovation processes and teams. Raj joined Beckman Coulter Life Sciences in 2016 as the Director of the Automation business unit. In this capacity, he led the turnaround of the Automation business with the launch of the Biomek i-Series and restructured the team, driving double digit organic growth. Raj joined Beckman Coulter from illumina, where he was the Head of the Clinical Core Products group, responsible for leading the company’s efforts to bring Next Generation Sequencing into the clinic. Prior to illumina, Raj was the Director of the Oncology and Genetics franchises at Abbott Laboratories which held a #1 share in oncology molecular diagnostics. Earlier in his career, Raj held a number of roles of increasing responsibilities in Research & Development at Ford Motor Company and was a Management Consultant at PriceWaterhouseCoopers.

Raj earned bachelor’s and master’s degrees in Mechanical Engineering from the University of Illinois at Urbana-Champaign and a master’s degree in Business Administration from Northwestern University’s Kellogg School of Management.